NCT06687291 Cognitive Impact Associated With Surgery For Gastric Or Esophageal Cancer
| NCT ID | NCT06687291 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Karolinska Institutet |
| Condition | Gastroesophageal Cancer (GC) |
| Study Type | OBSERVATIONAL |
| Enrollment | 130 participants |
| Start Date | 2025-02-13 |
| Primary Completion | 2026-11-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 130 participants in total. It began in 2025-02-13 with a primary completion date of 2026-11-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary objective of this observational study is to investigate the incidence of Post Operative Delirium (POD) after gastroesophageal cancer surgery. Secondary objectives are to investigate the relationship between POD, preoperative depression, frailty, quality of life, malnutrition and sarcopenia. Participants identified with POD will be asked (at the routine follow-up meeting after surgery) to participate in an qualitative interview, in order to understand the participant's experience of postoperative delirium. The main objective aims to answer: What is the incidence of POD after gastroesophageal cancer surgery.
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed with esophageal or gastric cancer, treated with (or without) chemotherapy and surgery. * Age ≥18 at the time for inclusion. * Participate on a voluntary basis and can (for any reason) end its participation during the study. * Capable of giving informed consent. Exclusion Criteria: * Patients with preoperative cognitive dysfunction such as dementia. * Patients who are inoperable due to metastases. * Patients unable to communicate due to severely impaired hearing and/or - seeing. * Patients with ongoing drug and/or alcohol abuse. * Patients who cannot give informed consent.
Contact & Investigator
Maria Lampi, PhD
PRINCIPAL INVESTIGATOR
Karolinska Institutet
Frequently Asked Questions
Who can join the NCT06687291 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Gastroesophageal Cancer (GC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06687291 currently recruiting?
Yes, NCT06687291 is actively recruiting participants. Contact the research team at marcus.nomm@ki.se for enrollment information.
Where is the NCT06687291 trial being conducted?
This trial is being conducted at Huddinge, Sweden.
Who is sponsoring the NCT06687291 clinical trial?
NCT06687291 is sponsored by Karolinska Institutet. The principal investigator is Maria Lampi, PhD at Karolinska Institutet. The trial plans to enroll 130 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.